Adjuvant Low Dose Aspirin in Colorectal Cancer
Condition: Colorectal Cancer · Sponsor: Anna Martling
About this study
ALASCCA is a randomized, parallel group, double blind, multicenter, placebo-controlled, biomarker-based study of adjuvant treatment with low dose aspirin in patients with colorectal cancer. Hypothesis is that patients diagnosed with colorectal cancer and somatic mutations in PI3K pathway can significantly improve survival if treated with low dose aspirin.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (32)
| Aarhus University Hospital | Aarhus, Denmark | — |
| Randers Regional Hospital | Randers, Denmark | — |
| Viborg Region Hospital | Viborg, Denmark | — |
| Jorvi Hospital | Espoo, Finland | — |
| Meilahti Tower Hospital | Helsinki, Finland | — |
| Akershus University Hospital | Oslo, Norway | — |
| Stavanger University Hospital | Stavanger, Norway | — |
| University Hospital of North Norway | Tromsø, Norway | — |
| St Olavs Hospital | Trondheim, Norway | — |
| Falu Hospital | Falun, Sweden | — |
| Eastern Hospital | Gothenburg, Sweden | — |
| Ryhov Hospital | Jönköping, Sweden | — |
+ 20 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02647099